Recent clinical research at the Risk Factor Modification Center, St. Michaelʹs Hospital, University of Toronto, Canada, has produced results indicating that Salba grain can assist in the prevention and treatment of cardiovascular disease in Type 2 diabetes. Dr. Vladimir Vuksan, Professor of Endocrinology and Nutritional Sciences in the Faculty ofMedicine at St. Michael’s Hospital was part the chief investigator of clinical studies on Salba.
Dr. Vuksan investigated Salba in randomized, acute and long‐term studies. In the studies, Salba reduced after‐meal blood glucose and plasma insulin levels, compared to controls. In a long term trial (12 weeks), supplementation of Conventional Therapy With the Novel Grain Salba (Salvia hispanica L.) ot also improved major and emerging Cardiovascular Risk Factors in Type 2 Diabetes2. Salba also reduced blood pressure, the major cardiovascular risk factor in individuals with Type 2 Diabetes and proved to be effective with respect to
reduction in inflammation and coagulation factors.
Press Release, June 24th, 2008: http://www.cdc.gov/media/pressrel/2008/r080624.htm
Comment Reply
Recent clinical research at the Risk Factor Modification Center, St. Michaelʹs Hospital, University of Toronto, Canada, has produced results indicating that Salba grain can assist in the prevention and treatment of cardiovascular disease in Type 2 diabetes. Dr. Vladimir Vuksan, Professor of Endocrinology and Nutritional Sciences in the Faculty ofMedicine at St. Michael’s Hospital was part the chief investigator of clinical studies on Salba.
Dr. Vuksan investigated Salba in randomized, acute and long‐term studies. In the studies, Salba reduced after‐meal blood glucose and plasma insulin levels, compared to controls. In a long term trial (12 weeks), supplementation of Conventional Therapy With the Novel Grain Salba (Salvia hispanica L.) ot also improved major and emerging Cardiovascular Risk Factors in Type 2 Diabetes2. Salba also reduced blood pressure, the major cardiovascular risk factor in individuals with Type 2 Diabetes and proved to be effective with respect to
reduction in inflammation and coagulation factors.
Press Release, June 24th, 2008: http://www.cdc.gov/media/pressrel/2008/r080624.htm
April 5, 2009 - 10:56pmThis Comment
Reply